单细胞分析揭示RETN+单核细胞来源的Resistin是HBV相关慢加急性肝衰竭的治疗靶点
本研究通过单细胞RNA测序分析HBV-ACLF患者外周血单核细胞异质性,发现RETN+单核细胞亚群在循环和肝脏中扩增,其产物Resistin通过激活PI3K/AKT通路抑制肝细胞凋亡,发挥肝保护和抗炎作用,血浆Resistin水平与炎症标志物、肝损伤、ACLF严重评分及短期死亡率呈负相关。
要点
- RETN+单核细胞在HBV-ACLF患者循环和肝脏中扩增,具抗炎和促消退特征。
- Resistin通过激活肝细胞PI3K/AKT通路、维持Bcl-2/Bax平衡抑制凋亡。
- 血浆Resistin水平与HBV-ACLF严重程度及短期死亡率呈负相关。
核心结论
- RETN+单核细胞是HBV-ACLF中富集的免疫调节亚群,其产物Resistin具有显著肝保护和抗炎作用,是潜在的免疫治疗靶点。
研究设计与样本
- 研究纳入健康对照(n=4)、急性失代偿患者(n=5)和ACLF患者(n=9)的外周血单个核细胞进行单细胞RNA测序,整合肝脏单细胞RNA测序、 bulk转录组学、多重免疫组化和体外功能实验,并在两种小鼠ACLF模型中验证候选靶点的体内作用。
主要发现
- 在HBV-ACLF患者循环和肝脏中鉴定出扩增的RETN+单核细胞亚群,其转录程序富集抗炎和促消退特征,包括MS1-B样特征。
- 白细胞介素-6通过JAK/STAT3/RUNX1信号轴促进RETN+单核细胞扩增。
- 在小鼠ACLF模型中,中和Resistin加重肝损伤、增加全身细胞因子水平和肝细胞凋亡;给予重组Resistin减轻肝损伤、降低炎性细胞因子水平并改善生存。
- 机制上,Resistin激活肝细胞PI3K/AKT信号,维持Bcl-2/Bax平衡并抑制内源性凋亡。
- 临床方面,HBV-ACLF患者血浆Resistin水平与全身炎症标志物、肝损伤、ACLF严重评分(MELD、CLIF-C ACLF评分)及短期死亡率呈负相关。
临床怎么用
- RETN+单核细胞和Resistin可作为HBV-ACLF免疫治疗的潜在靶点,血浆Resistin水平可能有助于评估疾病严重程度和短期预后。
局限性
- 单细胞RNA测序样本量较小(健康对照n=4、急性失代偿n=5、ACLF n=9),需更大规模研究验证。
- 体内验证仅在小鼠ACLF模型中进行,人体治疗干预的安全性和有效性尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute-on-chronic liver failure (ACLF) is characterised by intense systemic inflammation and high short-term mortality, yet effective targeted therapies are lacking. OBJECTIVE: To explore monocyte heterogeneity in HBV-related ACLF (HBV-ACLF) to identify specific subsets and associated therapeutic targets. DESIGN: Peripheral blood mononuclear cells from healthy controls (n=4), patients with acute decompensation (n=5), and patients with ACLF (n=9) underwent single-cell RNA sequencing (scRNA-seq). Findings were integrated with hepatic scRNA-seq, bulk transcriptomics, multiplex immunohistochemistry and in vitro functional assays. The in vivo roles of candidate targets were validated in two murine ACLF models. RESULTS: We identified a distinct RETN+ monocyte subset that was expanded in the circulation and liver of patients with HBV-ACLF. These RETN+ monocytes displayed a transcriptional programme enriched for anti-inflammatory and pro-resolving signatures, including MS1-B-like features. Interleukin-6 promoted the expansion of RETN+ monocyte via the JAK/STAT3/RUNX1 signalling axis. In murine ACLF models, neutralisation of Resistin exacerbated liver injury, increased systemic cytokine levels and augmented hepatocyte apoptosis. Conversely, administration of recombinant Resistin mitigated liver damage, diminished levels of inflammatory cytokines and improved survival. Mechanistically, Resistin activated PI3K/AKT signalling in hepatocytes, preserved the Bcl-2/Bax balance and suppressed intrinsic apoptosis. Clinically, plasma Resistin levels in HBV-ACLF patients inversely correlated with systemic inflammatory markers, liver injury, ACLF severity scores (Model for End-Stage Liver Disease, Chronic Liver Failure Consortium ACLF score) and short-term mortality. CONCLUSIONS: RETN+ monocytes constitute a distinct immunoregulatory subset enriched in HBV-ACLF, and their product, Resistin, exerts significant hepatoprotective and anti-inflammatory effects. These findings highlight RETN+ monocytes and Resistin as promising immunotherapeutic targets for HBV-ACLF.
引用
- Xu X, Chen J, Yu X, et al. Single-cell analysis identifies RETN+ monocyte-derived Resistin as a therapeutic target in hepatitis B virus-related acute-on-chronic liver failure. Gut. 2025. PMID: 41052916. doi:10.1136/gutjnl-2025-335998
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。